South Dakota Investment Council Sells 1,100 Shares of DexCom, Inc. (NASDAQ:DXCM)

South Dakota Investment Council lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 5.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,780 shares of the medical device company’s stock after selling 1,100 shares during the quarter. South Dakota Investment Council’s holdings in DexCom were worth $2,579,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in DXCM. Winslow Capital Management LLC bought a new stake in DexCom in the third quarter valued at about $173,120,000. Vaughan Nelson Investment Management L.P. increased its stake in DexCom by 16,943.0% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 1,459,730 shares of the medical device company’s stock valued at $136,193,000 after acquiring an additional 1,451,165 shares during the period. Westfield Capital Management Co. LP increased its stake in DexCom by 79.3% in the third quarter. Westfield Capital Management Co. LP now owns 1,847,865 shares of the medical device company’s stock valued at $172,406,000 after acquiring an additional 817,351 shares during the period. TimesSquare Capital Management LLC increased its stake in DexCom by 11,359.1% in the third quarter. TimesSquare Capital Management LLC now owns 733,380 shares of the medical device company’s stock valued at $68,424,000 after acquiring an additional 726,980 shares during the period. Finally, Sands Capital Management LLC increased its stake in DexCom by 4.3% in the third quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock valued at $1,274,541,000 after acquiring an additional 557,543 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on DXCM shares. Citigroup raised their price target on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. Raymond James raised their price target on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. Royal Bank of Canada started coverage on DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. UBS Group raised their price target on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $141.40.

DexCom Stock Up 2.9 %

NASDAQ:DXCM opened at $137.87 on Thursday. The stock’s fifty day simple moving average is $130.58 and its 200-day simple moving average is $117.88. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $54.60 billion, a P/E ratio of 105.25, a P/E/G ratio of 2.30 and a beta of 1.20. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.07. The firm had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company’s revenue for the quarter was up 26.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.34 earnings per share. Equities research analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the sale, the executive vice president now owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other DexCom news, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the transaction, the executive vice president now owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 14,639 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total value of $1,967,627.99. Following the transaction, the chief operating officer now directly owns 273,913 shares in the company, valued at approximately $36,816,646.33. The disclosure for this sale can be found here. Insiders have sold 189,375 shares of company stock valued at $25,530,859 in the last 90 days. 0.41% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.